• Profile

Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: A randomized clinical trial

JAMA Jul 13, 2019

Bastidas A, et al. - Through a phase 3, randomized, observer-blinded clinical trial of 1,846 patients who underwent autologous hematopoietic stem cell transplantation (HSCT), experts evaluated the effectiveness and adverse events associated with recombinant zoster vaccine in immunocompromised autologous HSCT recipients. Individuals randomly received 2 doses of either recombinant zoster vaccine (n=922) or placebo (n=924) given into the deltoid muscle. At least 1 herpes zoster event was verified in 49 vaccine and 135 placebo recipients resulting in 68.2% vaccine effectiveness during the 21-month median follow-up. Three out of 8 secondary endpoints showed decreases in postherpetic neuralgia incidence and of other herpes zoster-related complications and in the length of severe worst herpes zoster-associated pain. In 86% and 10% of vaccine and of placebo recipients, respectively, reported injection site reactions; pain was the most frequently seen in 84% of vaccine recipients. At all time points, unsolicited and serious adverse events, possibly immune-mediated diseases, and underlying disease relapses were comparable among groups. A 2-dose course of recombinant zoster vaccine vs placebo significantly lowered herpes zoster incidence over a median follow-up of 21 months in adults who underwent autologous HSCT.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen